Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

A study has suggested that the use of weight-loss jabs may be associated with wider health benefits, including a lower risk ...

According to an article in Reader’s Digest, growing evidence shows that dancing can boost brain health and help manage ...

The use of weight-loss jabs may be associated with wider health benefits including lower risk of stroke and dementia, a study ...

Harvard experts highlight the broad health benefits of exercise beyond weight loss, even with new diet drugs available.

To combat the rise in dementia patients, researchers suggested policies that will prevent heart disease, such as blood ...

Dementia cases in the U.S. are expected to double by 2060 when around 1 million Americans are projected to develop the memory ...

Pison Technology, led by veteran semiconductor executive John Croteau, is working with the watchmaker to integrate brain-sensing features into products.

GLP-1 agents "have an intricate web of various effects," Al-Aly said in a press briefing. For example, the analysis showed ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...